

Announcement Summary

Entity name CYCLOPHARM LIMITED

Announcement Type

New announcement

Date of this announcement

Monday January 25, 2021

The Proposed issue is:

☑ An offer of securities under a securities purchase plan
☑ A placement or other type of issue

Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan

ASX +security code	+Security description	Maximum Number of +securities to be issued
СҮС	ORDINARY FULLY PAID	576,923

+Record date Friday January 22, 2021

Offer closing date Monday February 15, 2021

+Issue date Friday February 19, 2021

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
СҮС	ORDINARY FULLY PAID	11,538,461

Proposed +issue date

Monday February 1, 2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

CYCLOPHARM LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ABN

Registration Number

74116931250

1.3 ASX issuer code

CYC

1.4 The announcement is

New announcement

1.5 Date of this announcement

Monday January 25, 2021

1.6 The Proposed issue is:

☑ An offer of +securities under a +securities purchase plan
☑ A placement or other type of issue



Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 - Are any of the following approvals required for the offer of +securities under the +securities purchase plan issue to be unconditional?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- · Another approval/condition external to the entity

🕑 No

Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

CYC : ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ASX +security code and description

CYC : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

576,923



Is the minimum acceptance unit based or dollar based? Dollar based (\$)

Please enter the minimum acceptance value

\$ 2,500

Is the maximum acceptance unit based or dollar based? ⓒ Dollar based (\$)

Please enter the maximum acceptance value

\$ 30,000

Describe all the applicable parcels available for this offer in number of securities or dollar value

The offer allows eligible shareholders to subscribe for one of the following parcels: \$2,500, \$5,000, \$7,500, \$10,000, \$12,500, \$15,000, \$17,500, \$20,000, \$22,500, \$25,000, \$27,500, \$30,000

Offer price details

Has the offer price been determined?

C Yes

In what currency will the offer	What is the offer price per
be made?	+security?
AUD - Australian Dollar	AUD 2.60000

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed? $\ensuremath{\mathfrak{S}}$ Yes

Describe the scale back arrangements

The Company may in its absolute discretion undertake a scale back of applications for New Shares to the extent and in the manner it sees fit.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

C Yes

Part 4C - Timetable



Proposed issue of securities

4C.1 Date of announcement of +security purchase plan

Monday January 25, 2021

4C.2 +Record date Friday January 22, 2021

4C.3 Date on which offer documents will be made available to investors

Monday February 1, 2021

4C.4 Offer open date

Monday February 1, 2021

4C.5 Offer closing date

Monday February 15, 2021

4C.6 Announcement of results

Wednesday February 17, 2021

4C.7 +Issue date

Friday February 19, 2021

Part 4D - Listing Rule requirements

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer? $\ensuremath{\mathfrak{C}}$ No

4E.2 Is the proposed offer to be underwritten? $\textcircled{}{\mathfrak{S}}$ No



4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

-

Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

Combined proceeds from the Placement and SPP will be used to finance accelerated expansion into the US market, expand Technegas use beyond the PE market, ongoing R&D activities, product & systems enhancement, working capital & placement costs.

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? $\textcircled{\sc No}$

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

Any country other than Australia, New Zealand and the United Kingdom.

4F.3 URL on the entity's website where investors can download information about the proposed offer

https://www.cyclopharm.com/announcements/

4F.4 Any other information the entity wishes to provide about the proposed offer

None



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

🕑 No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Securities class

Will the proposed issue of this +security include an offer of attaching +securities? ℭNo

Details of +securities proposed to be issued

ASX +security code and description

CYC : ORDINARY FULLY PAID

Number of +securities proposed to be issued

11,538,461

Offer price details

In what currency is the cash consideration being paid?

What is the issue price per +security? AUD 2.60000

AUD - Australian Dollar

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? ☑ Yes



Part 7C - Timetable

7C.1 Proposed +issue date

Monday February 1, 2021

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? ⓒ No

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

11,538,461 ordinary shares

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? ⓒ No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? ☑ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? ☑ No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue? ☑ Yes

7E.1a Who is the lead manager/broker?

Bell Potter Securities Limited

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

3.0% Management Fee and 2.0% Selling Fee of Placement proceeds



7E.2 Is the proposed issue to be underwritten? $\textcircled{\sc S}$ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Part 7F - Further Information

-

7F.01 The purpose(s) for which the entity is issuing the securities

Combined proceeds from the Placement and SPP will be used to finance accelerated expansion into the US market, expand Technegas use beyond the PE market, ongoing R&D activities, product & systems enhancement, working capital & placement costs.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No

7F.2 Any other information the entity wishes to provide about the proposed issue

None